Brief: Immuneering Announces FDA Clearance Of IND Application For Phase 1/2A Trial Of Imm-6-415 To Treat Advanced Solid Tumors With Raf Or Ras Mutations
Brief: Immuneering Completes Dose Escalation In Early-Stage Trial For Solid Tumors Treatment
U.S. STOCKS ON THE MOVE-CDW Corp, Bed Bath & Beyond, Elevance Health
U.S. STOCKS ON THE MOVE-United Airlines, Abbott Labs, Shift4 Payments
U.S. STOCKS ON THE MOVE-Tesla, Morgan Stanley, Lockheed Martin
U.S. STOCKS ON THE MOVE-Western Alliance, WeWork, Baker Hughes
Mizuho doubles PT on Immuneering over positive cancer drug data
U.S. RESEARCH ROUNDUP-First Solar, Lockheed Martin, MSCI
Immuneering up as cancer drug study timeline accelerated after positive data
Brief: Immuneering Corp Files For Class A Common Stock Offering, Size Not Disclosed - SEC Filing
Brief: Immuneering Announces $30 Million Underwritten Offering
Brief: Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic And Safety Data For Imm-1-104 Universal-Ras Program Accelerates Study Timeline
Brief: Immuneering To Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling And Safety Data For Universal-Ras Program Imm-1-104 At American Association For Cancer Research Annual Meeting 2023
U.S. RESEARCH ROUNDUP-Globus Medical, Philip Morris International, Vail Resorts
Brief: Immuneering Reports Q4 And Full Year 2022 Financial Results And Provides Business Updates
Brief: Immuneering Doses First Patient In Early-to-Mid Stage Study Of Drug for Solid Tumors
Brief: Immuneering Reports Third Quarter Results
Brief: Immuneering Appoints Leah R. Neufeld As Chief People Officer
Immuneering gains on FDA nod for early-stage study on cancer drug